Asa Rén, a leading DNA data startup based in Indonesia, has announced the closing of a new early-stage round of funding of $8.15 million.

Asa Rén offers a direct-to-consumer DNA test that can generate more than 360 reports on predisposed health risks and other ancestry-genetic analyses for children and adults allowing them to understand and manage their own healthcare data through their genetic profile.

The DNA data startup has signed service agreements with more than 47 prominent hospital and clinic partners and is expecting to grow its distribution footprint to more than 60 hospital and clinic partners by the end of 2023.

With the funding, the company aims to accelerate drug discovery and personalized treatments for Southeast Asia’s healthcare industry by developing clinical-genomic databases from both healthy and confirmed diagnostic populations.

In addition, the new capital will allow the company to expand its efforts in deepening its digital capabilities, developing clinical bioinformatics, an electronic health passport, and a clinical-genomic database focused on non-communicable diseases.

This oversubscribed round was co-led by Top Harvest Capital (Silicon Valley USA), Kejora Capital (Kejora-SBI Orbit Fund and Orbit Capital Malaysia), and Marcy Venture Partners (Silicon Valley USA). Northstar Ventures, Naya Capital, PT Diagnos Laboratorium Utama Tbk, and a number of prominent angel investors also participated in the round.